Section of Hematology-Oncology, Department of Medicine (EEV, TYS), Section of Otolaryngology and Head and Neck Surgery, Department of Surgery (NA), and The University of Chicago Comprehensive Cancer Center (EEV, TYS), The University of Chicago, Chicago, IL.
J Natl Cancer Inst. 2015 Dec 9;107(12):djv344. doi: 10.1093/jnci/djv344. Print 2015 Dec.
Over the last two decades, it has been recognized that head and neck cancers, primarily in the oropharynx, can be a distinct entity that is causally related to human papilloma virus (HPV). Fakhry et al. established in 2008 that such tumors have a strikingly better prognosis with improved responsiveness to chemotherapy as well as chemoradiotherapy and favorable survival rates. Since then, new studies have contributed to our increased understanding of this new entity, ranging from a detailed understanding of the genetic fingerprint and risk modifiers such as smoking to successful early attempts to personalize therapy with de-escalation in the definitive intent treatment setting and specific evaluation of targeted therapies in this patient population. This Commentary seeks to summarize the state of the art of our understanding of HPV-associated head and neck cancers that has emerged since the publication of seminal findings by Fakhry et al.
在过去的二十年中，人们已经认识到，头颈部癌症（主要是口咽癌）可能是一种与人类乳头瘤病毒（HPV）有关的独特实体。Fakhry 等人在 2008 年证实，此类肿瘤的预后明显更好，对化疗以及放化疗的反应性提高，生存率也更高。从那时起，新的研究增加了我们对这种新实体的认识，包括对遗传指纹和风险修饰物（如吸烟）的详细了解，到在明确治疗意向的治疗环境中成功地尝试对治疗进行降级以实现个体化治疗，以及对头颈部癌症患者人群中的靶向治疗进行具体评估。本述评旨在总结自 Fakhry 等人发表开创性研究结果以来，我们对头颈部 HPV 相关性癌症认识的最新进展。
